Dong Yan1,#, Chunxiao Li2,#, Yantong Zhou2, Xue Yan1, Weihua Zhi1, Haili Qian2,*, Yue Han1,*
Oncologie, Vol.24, No.1, pp. 101-111, 2022, DOI:10.32604/oncologie.2022.020357
Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance
is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets
to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic
alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic
to identify candidate drugs that might hold promise when used in combination with sorafenib. Our results
revealed that… More >
Login
Register
